Detection of antihypertensive drug related genes by gene array

Abstract

Abstract: AIM: To detect and type the antihypertensive drug related genes of 219 samples and validate the reliability of the gene microarray method in this experiment. METHODS: Genotype analysis of five antihypertensive drug related genes was performed using gene microarray. And the results of gene microarray analysis were compared with the results of standard ABI sequencing or fragment length polymorphism. RESULTS: Genotyping results of two methods had a high consistency. CONCLUSION: The gene microarray method used in our experiment is simple, efficient and reliable.

Key words: Hypertension, Gene microarray, Gene polymorphism

CLC Number:

R969

YANG Fan, ZHAO Gang-tao, DING Yuan-yuan, BIAN Jia-ming, XIAO Le-dong, XU Jing-feng. Detection of antihypertensive drug related genes by gene array[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1251-1255.

References

[1] 王瑞石,胡伟新,李瑛. 高血压病的药物基因组学研究[J]. 肾脏病与透析肾移植杂志,2003,12(3):262-267.
[2] 徐国辰,刘文玲,梅其炳,等. 药物基因组学对心血管病个体化治疗的启示[J]. 中国药学杂志,2005,40(3):172.
[3] Ji L, Pan SX, Wu JM, et al. Genetic polymorphisms of CYP2D6 in Chinese mainland[J]. Chin Med J (Engl), 2002, 115(12):1780-1784.
[4] 王睿,向倩,陈騉,等. 细胞色素P450氧化酶基因多态性对药物代谢影响的研究进展[J]. 中国临床药理学杂志,2004,2(88):134-138.
[5] Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance[J]. Curr Drug Metab, 2009, 10(7):781-834.
[6] Joy MS, Dornbrook-Lavender K, Blaisdell J, et al. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases[J]. Eur J Clin Pharmacol, 2009, 65(9):947-953.
[7] 杨天伦,陈美芳,谢启应. 沙坦类药物代谢酶CYP2C9和受体AT1基因的遗传多态性在高血压患者中的分布体征[J]. 中南药学,2007,5(1):6-9.
[8] Yoo SM, Choi JH, Lee SY, et al. Applications of DNA microarray in disease diagnostics[J]. J Microbiol Biotechnol, 2009, 19(7):635-646.
[9] Gemignani F, Perra C, Landi S, et al. Reliable detection of β-thalassemia and G6PD mutations by a DNA microarray[J]. Clin Chem,2002, 48(11):2051-2054.
[10] Batchelor M, Hopkins KL, Liebana E, et al. Development of a miniaturised microarray-based assay for the rapid identification of antimicrobial resistance genes in Gram-negative bacteria[J]. Int J Antimicrob Agents, 2008, 31(5):440-451.
[11] 王国建,戴朴,韩东一,等. 基因芯片技术在非综合征性耳聋快速基因诊断中的应用研究[J]. 中华耳科学杂志,2008,6(1):61-66.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[5]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[6]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[7]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[8]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[9]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[10]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[11]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[12]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[13]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[14]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[15]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.